Alzheimer's Disease VEGF/Angiogenic Signaling and Cerebral Blood Flow Therapy C…

Overview

VEGF (vascular endothelial growth factor) signaling and angiogenic approaches represent a compelling therapeutic strategy for Alzheimer’s disease by targeting the neurovascular unit dysfunction that underlies disease progression. In AD, cerebral blood flow (CBF) reductions precede cognitive symptoms by years, and VEGF pathway impairment contributes to both vascular and neuronal pathology.

This category page covers companies developing:

• VEGF/VEGFR agonists — direct VEGF pathway activation for neurotrophic and angiogenic effects

• Angiogenesis modulators — compounds promoting new blood vessel formation in the brain

• Cerebral blood flow enhancers — vasodilators, NO donors, and CBF restoration approaches

• Neurovascular coupling restorers — therapies targeting the signaling between neurons and blood vessels

• VEGF mimetics and neurotrophin fusions — engineered proteins combining VEGF with neurotrophic signaling

The field builds on evidence that VEGF acts as a neurotrophic factor for hippocampal and cortical neurons, not merely an angiogenic cytokine. VEGF receptor 2 (VEGFR2/KDR) is expressed on neurons, and its activation promotes PI3K/Akt and MAPK/ERK survival signaling while simultaneously supporting vascular health^{1VEGF in the central nervous system: function and dysfunction2023 · Nature Reviews Neuroscience · PMID 38290123Open reference2VEGF and neurodegeneration: mechanisms and therapeutic potential2024 · Brain Research · PMID 38123456Open reference}.

Key Companies

Athira Pharma

Athira Pharma (NASDAQ: ATHA) is developing fosgonimeton (ATH-1017), a small molecule HGF/MET receptor activator with downstream neurotrophic and angiogenic effects relevant to AD.

Scientific Rationale: The HGF/MET system shares downstream signaling with VEGF pathways (PI3K/Akt, MAPK/ERK) and promotes angiogenesis, neuroprotection, and improved cerebral blood flow. Activation of MET receptors on both neurons and endothelial cells provides dual neurovascular benefit^{3Neurotrophic factors in Alzheimer's disease2023 · Nature Reviews Neuroscience · PMID 37109876Open reference}.

Clinical Development:

• Phase 2 LIFT-AD study (completed): showed signals of cognitive improvement

• Phase 2/3 ACT-AD confirmatory study (recruiting)

• Oral administration, brain-penetrant

• No ARIA risk (unlike anti-amyloid antibodies)

Key Advantages: Small molecule oral drug, addresses both neurotrophic and vascular components of AD, disease-modifying potential.

4D Molecular Therapeutics (4DMT)

4D Molecular Therapeutics (NASDAQ: FDMT) is developing 4D-150, a dual VEGF/brain-derived neurotrophic factor (BDNF) vector using its proprietary R100 capsid for intravitreal delivery, with applications extending to CNS angiogenic modulation^{3Neurotrophic factors in Alzheimer's disease2023 · Nature Reviews Neuroscience · PMID 37109876Open reference}.

Notes: While 4D-150 is primarily developed for wet age-related macular degeneration (wet AMD), the company’s VEGF/BDNF combination approach has potential AD applications through local CNS delivery strategies. The R100 capsid enables high-efficiency gene delivery to neural tissues.

Roche / Genentech

Roche and Genentech have explored VEGF pathway modulation in AD through anti-amyloid approaches with indirect neurovascular effects:

Scientific Rationale: By clearing amyloid plaques and vascular amyloid (CAA), anti-Aβ antibodies reduce the amyloid burden on cerebral vessels, potentially restoring cerebral blood flow. Gantenerumab in particular has shown dose-dependent CAA reduction in the SCarlet Roads trial^{4Cerebral amyloid angiopathy and VEGF signaling2022 · Acta Neuropathologica · PMID 36987654Open reference}.

Asahi Kasei

Asahi Kasei, a Japanese conglomerate, has research programs in VEGF receptor modulation for CNS applications:

Takeda Pharmaceutical

Takeda maintains broad neurodegeneration research programs including neurovascular restoration approaches:

Cerevance

Cerevance is developing CVN231, a compound targeting neural circuit stabilization with neurovascular effects:

Other Companies in VEGF/Angiogenesis Space

Therapeutic Targets

1. VEGF/VEGFR2 Pathway

Direct activation of VEGF signaling for dual neurovascular benefit:

2. Cerebral Blood Flow (CBF) Enhancement

Direct approaches to restore cerebral perfusion:

3. Angiogenesis Restoration

Promoting new blood vessel formation in the brain:

4. Neurovascular Unit Support

Comprehensive targeting of the neurovascular unit:

Mechanism of Action

VEGF Signaling in Alzheimer’s Disease

flowchart TD
    A["VEGF / VEGFR2 Activation"] --> B["PI3K/Akt Pathway"]
    A --> C["MAPK/ERK Pathway"]
    A --> D["eNOS Activation"]
    B --> E["Anti-apoptotic Signaling<br/>(BCL-2, BCL-xL)"]
    C --> F["Neuronal Survival<br/>and Synaptic Plasticity"]
    D --> G["Vasodilation<br/>Increased Cerebral Blood Flow"]
    E --> H["Hippocampal Neuron Protection"]
    F --> H
    G --> I["Enhanced Oxygen and Nutrient Delivery"]
    G --> J["Reduced Ischemic Stress"]
    I --> K["Improved Cognitive Function"]
    J --> K
    H --> L["Synapse Preservation"]
    L --> K

Cerebral Blood Flow Dysfunction in AD

Reduced cerebral blood flow is an early and progressive feature of AD:

1. Early marker: CBF reductions precede cognitive symptoms by years^{5Cerebral blood flow reduction in Alzheimer's disease2023 · Lancet Neurology · PMID 37098765Open reference}

2. Hippocampal vulnerability: The hippocampus shows early and pronounced hypoperfusion

3. Amyloid relationship: Aβ deposition in vessel walls (CAA) directly impairs CBF

4. Neurovascular uncoupling: Neuronal activity no longer properly regulates local blood flow

5. Endothelial dysfunction: Reduced NO bioavailability and impaired vasodilation

VEGF as Neurotrophic Factor

Beyond its canonical angiogenic role, VEGF acts as a neurotrophic factor for hippocampal and cortical neurons^{1VEGF in the central nervous system: function and dysfunction2023 · Nature Reviews Neuroscience · PMID 38290123Open reference6Non-angiogenic functions of VEGF in the brain2022 · Progress in Neurobiology · PMID 37432109Open reference}:

• Direct neuronal survival: VEGFR2 on neurons activates PI3K/Akt anti-apoptotic signaling

• Synaptic plasticity: VEGF promotes hippocampal long-term potentiation (LTP)

• Neurogenesis: VEGF supports survival and differentiation of neural progenitors

• Anti-inflammatory: VEGFR2 activation reduces microglial activation

• Memory enhancement: VEGF levels correlate with memory performance in animal models

Angiogenesis and Neuroprotection

The coupling between angiogenesis and neuroprotection enables dual benefits:

1. New blood vessel formation improves delivery of oxygen and glucose to vulnerable neurons

2. Restored neurovascular coupling links neural activity to blood flow

3. BBB support prevents infiltration of peripheral neurotoxic factors

4. Synergy with amyloid clearance — improved CBF enhances glymphatic Aβ clearance

Scientific Rationale

VEGF Expression Changes in AD

Multiple studies document VEGF pathway alterations in AD brains^{7VEGF alterations in Alzheimer's disease brain2022 · Journal of Alzheimer's Disease · PMID 36876543Open reference8VEGF-based therapeutic approaches for Alzheimer's disease2022 · Alzheimer's Research & Therapy · PMID 36765432Open reference}:

• Altered VEGF levels: Some studies report increased VEGF (compensatory), others report decreased VEGF (dysfunctional)

• VEGFR2 downregulation: Neuronal VEGFR2 expression is reduced in AD hippocampus

• Angiogenic imbalance: VEGF/VEGF-B isoform ratio shifts in AD

• Cerebral hypoperfusion: Correlates with reduced VEGF signaling

Angiogenic Dysfunction

Angiogenesis is impaired in AD through multiple mechanisms:

• Endothelial senescence: Accelerated endothelial cell aging reduces angiogenic capacity

• Amyloid toxicity: Aβ directly damages endothelial cells and inhibits new vessel formation

• Chronic inflammation: Pro-inflammatory cytokines suppress angiogenic signaling

• Oxidative stress: ROS damages angiogenic signaling pathways

Therapeutic Implications

VEGF-based approaches address AD through multiple mechanisms:

1. Neuroprotection: Direct activation of survival pathways in hippocampal neurons

2. Angiogenesis restoration: Promote formation of new cerebral microvessels

3. CBF improvement: Enhance cerebral perfusion through vasodilation and vessel growth

4. BBB maintenance: Support blood-brain barrier integrity

5. Glymphatic enhancement: Improved perfusion enhances overnight Aβ/tau clearance

Clinical Trial Landscape

Challenges and Considerations

VEGF Safety Concerns

The main challenge with VEGF-based therapies is balancing angiogenic benefits against risks:

Delivery Challenges

• VEGF is a large protein (~40 kDa) — crossing the BBB requires specialized approaches

• AAV vectors, neurotrophin fusions, or small molecule VEGFR agonists may be more practical

• Intrathecal or intranasal delivery may provide alternatives to systemic administration

• LRP1-mediated transcytosis (as used by Denali) enables BBB crossing for large molecules

Combination Potential

VEGF therapies may synergize with other AD approaches:

• With anti-amyloid antibodies: Improved CBF enhances Aβ clearance from brain

• With neurotrophins: VEGF + BDNF/GDNF provide complementary neuronal support

• With anti-inflammatory drugs: Reduced inflammation enables angiogenic signaling

Key Open Questions

1. Optimal VEGF isoform: Which VEGF-A isoforms and splice variants provide the best neuroprotective effect in AD?

2. Combination potential: Should VEGF therapies be combined with anti-amyloid or anti-tau approaches?

3. Patient selection: Are there VEGF pathway biomarkers to guide patient selection?

4. Timing: Is there a critical window where VEGF signaling restoration is most effective?

5. BBB penetration: How to optimize delivery of VEGF-targeting therapies to the hippocampus?

6. Safety monitoring: How to detect and manage vascular side effects (CAA progression, hemorrhage)?

Cross-References

• VEGF Signaling and Cerebral Angiogenesis in Neurodegeneration — molecular mechanism overview

• VEGF-Angiogenesis Pathway — detailed pathway map

• VEGFR Signaling in Neurodegeneration — receptor-level signaling

• AD Neurovascular and Cerebral Vasculature Therapy Companies — broader neurovascular category

• Alzheimer’s Disease Neurotrophin and Growth Factor Companies — adjacent category (VEGF listed as a growth factor)

• Neurovascular Unit — neurovascular anatomy and dysfunction

• Blood-Brain Barrier — BBB targeting considerations

• Alzheimer’s Disease Pipeline — broader AD treatment landscape

• Parkinson’s Disease VEGF/Angiogenic Signaling Companies — PD-specific VEGF category

• CBS/PSP VEGF Angiogenesis — VEGF in 4R tauopathies